In vitro-in vivo discordance with humanized piperacillin-tazobactam exposures against piperacillin-tazobactam-resistant/pan-β-lactam-susceptible Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7527-7529

  Monogue, M L ^a   Nicolau, D P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; COLISTIN; CULTURE MEDIUM; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ESCHERICHIA COLI; EXPERIMENTAL PNEUMONIA; FEMALE; GENETIC VARIABILITY; GENOTYPE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CULTURE MEDIUM; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GROWTH, DEVELOPMENT AND AGING; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEUTROPENIA; PATHOLOGY; PHARMACOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLISTIN; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84996477068     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01208-16     Document Type: Article

References (16)

1. Sutherland CA, Nicolau DP. 2015. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin Ther 37:1564-1571. http://dx.doi.org/10.1016/j.clinthera.2015.05.501.
2. Mediavilla JR, Schneider Z, Nwaigwe C, Chavda K, Chen L, Satlin M, Jenkins SG, Nicolau DP, Kreiswirth BN. 2015. Molecular characterization of cephalosporin/carbapenem/monobactam susceptible but piperacillin-tazobactam (TZP) resistant E. coli, abstr 1181. Abstr ID Week 2015, San Diego, CA.
3. Díaz-Martín A, Martínez-González ML, Ferrer R, Ortiz-Leyba C, Piacentini E, Lopez-Pueyo MJ, Martín-Loeches I, Levy MM, Artigas A, Garnacho-Montero J. 2012. Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. Crit Care 16:R223. http://dx.doi.org/10.1186/cc11869.
4. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother 56:544-549. http://dx.doi.org/10.1128/AAC.01752-10.
6. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. 2002. Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375g q4hr and 4.5g q6hr. Chemotherapy 48:59-63. http://dx.doi.org/10.1159/000057663.
7. Beam TR. 1983. Recent developments in antimicrobial therapy with beta-lactam antibiotics. J Med 14:307-336.
8. Komuro M, Kakuo H, Matsushita H, Shimada J. 1994. Inhibition of the renal excretion of tazobactam by piperacillin. J Antimicrob Chemother 34:555-564. http://dx.doi.org/10.1093/jac/34.4.555.
9. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. http://dx.doi.org/10.1086/516284.
10. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamics model. Antimicrob Agents Chemother 54:804-810. http://dx.doi.org/10.1128/AAC.01190-09.
11. Bulik CC, Nicolau DP. 2010. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 54:4112-4115. http://dx.doi.org/10.1128/AAC.00026-10.
12. Bulik CC, Nicolau DP. 2011. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 55:3002-3004. http://dx.doi.org/10.1128/AAC.01420-10.
13. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:6137-6146. http://dx.doi.org/10.1128/AAC.00851-12.
14. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. 2014. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58:3366-3372. http://dx.doi.org/10.1128/AAC.00080-14.
15. Johnson JR, Thuras P, Johnston BD, Weissman SJ, Limaye AP, Riddell K, Scholes D, Tchesnokova V, Sokurenko E. 2016. The pandemic H30 subclone of Escherichia coli sequence type 131 is associated with persistent infections and adverse outcomes independent from its multidrug resistance and associations with compromised hosts. Clin Infect Dis 15:1529-1536. http://dx.doi.org/10.1093/cid/ciw193.
16. NDM-1 on fitness and pathogenicity of Escherichia coli and Klebsiella pneumoniae. Int J Antimicrob Agents 47:430-435. http://dx.doi.org/10.1016/j.ijantimicag.2016.02.019.